Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 6/20 | 0.37 |
| ▸ | PER2 | O15055 | 3/20 | 0.33 |
| ▸ | CRY1 | Q16526 | 3/20 | 0.33 |
| ▸ | CRY2 | Q49AN0 | 3/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | PFKFB4 | Q16877 | 2/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684596 | 0.91 | PPARD (0.38) | CMA1PTPN1FFAR1 | |
| SCHEMBL3682436 | 0.91 | PFKFB3 (0.38) | CMA1PFKFB3PFKFB4PTGDR2 | |
| SCHEMBL3689019 | 0.85 | PPARD (0.38) | CMA1 | |
| SCHEMBL3696840 | 0.83 | CMA1 (0.38) | CMA1PTPN1FFAR1 | |
| SCHEMBL3679311 | 0.82 | PPARD (0.41) | PFKFB3PFKFB4PTGDR2 | |
| SCHEMBL3692506 | 0.81 | PFKFB3 (0.36) | CMA1PFKFB3PFKFB4 | |
| SCHEMBL3681157 | 0.81 | PPARD (0.39) | PTPN1FFAR1 | |
| SCHEMBL3685322 | 0.81 | CMA1 (0.36) | CMA1PER2CRY1CRY2PFKFB3 | |
| SCHEMBL3681651 | 0.80 | PPARD (0.42) | CMA1FFAR1 | |
| SCHEMBL3694979 | 0.79 | PPARD (0.41) | CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | CMA1 4529/4885PER2 782/4885CRY1 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.